VIR vs. PCVX, ABCM, DNLI, CRSP, DNA, BEAM, IMCR, IMVT, RVMD, and KRYS
Should you be buying Vir Biotechnology stock or one of its competitors? The main competitors of Vir Biotechnology include Vaxcyte (PCVX), Abcam (ABCM), Denali Therapeutics (DNLI), CRISPR Therapeutics (CRSP), Ginkgo Bioworks (DNA), Beam Therapeutics (BEAM), Immunocore (IMCR), Immunovant (IMVT), Revolution Medicines (RVMD), and Krystal Biotech (KRYS). These companies are all part of the "biological products, except diagnostic" industry.
Vir Biotechnology vs.
Vaxcyte (NASDAQ:PCVX) and Vir Biotechnology (NASDAQ:VIR) are both mid-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, valuation, media sentiment, analyst recommendations, profitability, earnings, dividends, community ranking and institutional ownership.
Vir Biotechnology has higher revenue and earnings than Vaxcyte. Vaxcyte is trading at a lower price-to-earnings ratio than Vir Biotechnology, indicating that it is currently the more affordable of the two stocks.
Vaxcyte has a beta of 1, meaning that its share price has a similar volatility profile to the S&P 500.Comparatively, Vir Biotechnology has a beta of 0.26, meaning that its share price is 74% less volatile than the S&P 500.
Vir Biotechnology's return on equity of 25.22% beat Vaxcyte's return on equity.
Vaxcyte presently has a consensus price target of $64.83, suggesting a potential upside of 71.15%. Vir Biotechnology has a consensus price target of $51.29, suggesting a potential upside of 130.39%. Given Vir Biotechnology's higher possible upside, analysts plainly believe Vir Biotechnology is more favorable than Vaxcyte.
In the previous week, Vir Biotechnology had 2 more articles in the media than Vaxcyte. MarketBeat recorded 2 mentions for Vir Biotechnology and 0 mentions for Vaxcyte. Vir Biotechnology's average media sentiment score of 1.33 beat Vaxcyte's score of 0.58 indicating that Vir Biotechnology is being referred to more favorably in the news media.
71.5% of Vaxcyte shares are owned by institutional investors. Comparatively, 75.0% of Vir Biotechnology shares are owned by institutional investors. 13.7% of Vaxcyte shares are owned by insiders. Comparatively, 22.4% of Vir Biotechnology shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Vir Biotechnology received 7 more outperform votes than Vaxcyte when rated by MarketBeat users. However, 60.61% of users gave Vaxcyte an outperform vote while only 45.76% of users gave Vir Biotechnology an outperform vote.
Summary
Vir Biotechnology beats Vaxcyte on 13 of the 16 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding VIR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Vir Biotechnology Competitors List
